Group 1 - The core announcement is that CROSSJECT has made its 2024 annual financial report available to the public and filed it with the French Financial Markets Authority [2][5] - CROSSJECT is a pharmaceutical company specializing in the advanced development and registration of ZEPIZURE®, an emergency solution for managing epilepsy crises [2][3] - The company has secured a $60 million contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the research and development of ZEPIZURE® [3][4] Group 2 - ZEPIZURE® utilizes the award-winning needle-free auto-injector ZENEO®, allowing untrained patients and caregivers to perform intramuscular injections easily and instantly in emergency situations [3] - CROSSJECT is also developing additional products for emergency treatment of allergic shocks, adrenal insufficiencies, opioid overdoses, and asthma attacks [3]
Mise à disposition du rapport financier annuel 2024
Globenewswire·2025-04-30 15:45